Clinical candidates for carcinoembryonic antigen+ (CEA) and mesothelin+ (MSLN) cancers nominated
Science
Overview
Technology Platform
Manufacturing
Publications
Pipeline
Overview
About Us
Overview
Leadership
Board of Directors
Scientific Advisory Board
Investors
Partners
Investors
Overview
Newsroom
News
Media Inquiries
Careers
Join the Team
Contact
General Inquires
